DRG 285 Overview

DRG 285 covers inpatient hospitalizations for patients with acute myocardial infarction who expire during the admission and do not have a Major Complication or Comorbidity or a Complication or Comorbidity. This Diagnosis-Related Group captures cases where the primary clinical event is fatal acute myocardial infarction and resource use is influenced by end-of-life care, diagnostic evaluation, and any interventions attempted prior to death. It matters for Medicare payment because classification into this Diagnosis-Related Group determines the prospective payment and reflects clinical and coding documentation tied to mortality and resource consumption. Accurate assignment affects hospital reimbursement under Centers for Medicare & Medicaid Services inpatient prospective payment policies.

Across commercial payers the observed payment range runs from about $370 to $21K, with payer means spanning roughly $5.6K to $10K. The widest single-payer spread appears with Anthem (min $390 to max $21K). See the payer table and chart below for payer-specific quartiles and full distributions for Blue Cross Blue Shield, UnitedHealth Group, Cigna, Aetna, and Anthem.

The CMS 2023 data represent national Medicare fee-for-service inpatient payments published under the CMS Provider Utilization and Payment Data program. The table below shows average total payment ($5.4k), average submitted covered charges ($30.7k), average Medicare payment ($3.8k), and total discharges (131).

• Acute-phase interventional trials evaluating timing and methods of reperfusion and supportive care in patients with fatal acute myocardial infarction: these studies focus on immediate hospital management strategies for patients presenting with ST-elevation or large non–ST-elevation myocardial infarction who are hemodynamically unstable and at highest short-term mortality risk. Investigators compare protocols for rapid coronary reperfusion, adjunctive antithrombotic strategies, and ICU-level supportive measures to determine impact on in-hospital survival and organ failure; results inform acute care pathways and resource allocation decisions for providers and payers caring for high-risk AMI patients.
• Comparative effectiveness and prognostic cohort studies of comorbidity-driven care bundles in elderly or multimorbid AMI patients: these observational or pragmatic randomized studies examine how different inpatient care bundles (for example, protocols that integrate heart failure management, renal protection, and delirium prevention) affect short-term mortality and complications among older adults or those with significant comorbid conditions who experience AMI and die during hospitalization. These trials address which integrated approaches reduce length of stay, complications, and downstream costs, providing actionable evidence for clinicians and payers to optimize care for complex patients commonly grouped in this DRG.
• Post-mortem and quality-of-care review studies linking prehospital and in-hospital processes to mortality outcomes for AMI patients: these investigations analyze registry, chart review, and system-level data to identify delays in symptom recognition, EMS response, door-to-treatment times, and in-hospital decision points associated with in-hospital death without major complications recorded. By characterizing preventable process failures and variation across hospitals, this research supports quality improvement programs and payer-driven performance incentives aimed at reducing preventable AMI deaths and aligning reimbursement and care pathways with best practices.